Mereo Biopharma Group PLC
NASDAQ:MREO

Watchlist Manager
Mereo Biopharma Group PLC Logo
Mereo Biopharma Group PLC
NASDAQ:MREO
Watchlist
Price: 3.72 USD 1.09% Market Closed
Market Cap: 572.3m USD
Have any thoughts about
Mereo Biopharma Group PLC?
Write Note

Mereo Biopharma Group PLC
Net Income (Common)

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Mereo Biopharma Group PLC
Net Income (Common) Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Net Income (Common) CAGR 3Y CAGR 5Y CAGR 10Y
Mereo Biopharma Group PLC
NASDAQ:MREO
Net Income (Common)
-ÂŁ29.5m
CAGR 3-Years
44%
CAGR 5-Years
2%
CAGR 10-Years
N/A
Centessa Pharmaceuticals PLC
NASDAQ:CNTA
Net Income (Common)
-$151.1m
CAGR 3-Years
-142%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Autolus Therapeutics PLC
NASDAQ:AUTL
Net Income (Common)
-$208.4m
CAGR 3-Years
-14%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Bicycle Therapeutics PLC
NASDAQ:BCYC
Net Income (Common)
-$166.3m
CAGR 3-Years
-36%
CAGR 5-Years
-37%
CAGR 10-Years
N/A
Immunocore Holdings PLC
NASDAQ:IMCR
Net Income (Common)
-ÂŁ55.3m
CAGR 3-Years
9%
CAGR 5-Years
5%
CAGR 10-Years
N/A
Genus PLC
LSE:GNS
Net Income (Common)
ÂŁ7.9m
CAGR 3-Years
-45%
CAGR 5-Years
0%
CAGR 10-Years
-12%
No Stocks Found

Mereo Biopharma Group PLC
Glance View

Market Cap
572.3m USD
Industry
Biotechnology

Mereo BioPharma Group Plc is a biopharmaceutical company, which engages in the development and commercialization of therapeutics that aim to improve outcomes for oncology and rare diseases. The firm is focused on oncology and rare diseases. The firm is focused on development and commercialization of therapeutic pharmaceutical products. Its pipeline consists of a diversified portfolio of clinical-stage product candidates, Etigilimab (MPH-313) for patients with advanced or metastatic solid tumors; Alvelestat (MPH-966) for the treatment of severe Alpha-1 Antitrypsin Deficiency (AATD) and coronavirus disease; Setrusumab (BPS-804) for the treatment of Osteogenesis Imperfecta (OI); Navicixizumab (OMP-305B83) for the treatment of platinum-resistant ovarian cancer; Acumapimod (BCT-197) for the treatment of acute exacerbations of chronic obstructive pulmonary disease (AECOPD) and Leflutrozole (BGS-649) for the treatment of male infertility associated with hypogonadotropic hypogonadism (HH).

MREO Intrinsic Value
2.28 USD
Overvaluation 39%
Intrinsic Value
Price

See Also

What is Mereo Biopharma Group PLC's Net Income (Common)?
Net Income (Common)
-29.5m GBP

Based on the financial report for Dec 31, 2023, Mereo Biopharma Group PLC's Net Income (Common) amounts to -29.5m GBP.

What is Mereo Biopharma Group PLC's Net Income (Common) growth rate?
Net Income (Common) CAGR 5Y
2%

Over the last year, the Net Income (Common) growth was 14%. The average annual Net Income (Common) growth rates for Mereo Biopharma Group PLC have been 44% over the past three years , 2% over the past five years .

Back to Top